CurrentcareoregonPolicy N/A

Multiple sclerosis disease-modifying agents (fingolimod, Mayzent)

Customize your policy alerts

Sign up for all careoregon policy alerts

Know when careoregon releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Prior authorization guideline for coverage of fingolimod (generic) and Mayzent (siponimod) for members with multiple sclerosis; specifies clinical criteria, prescriber requirements, and approval durations for CareOregon members.

Policy Summary

Payercareoregon

PolicyMultiple sclerosis disease-modifying agents (fingolimod, Mayzent)

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJul 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization with documentation showing neurologist involvement, diagnosis, prior therapy history, and required MRI/relapse evidence when applicable.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

LifetimeApproval length

NeurologistPrescriber requirement

≥1 relapseRequired relapse (Mayzent)

≥1Gadolinium lesion

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentcareoregonPolicy N/A

Multiple sclerosis disease-modifying agents (fingolimod, Mayzent)

Customize your policy alerts

Sign up for all careoregon policy alerts

Know when careoregon releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payercareoregon

PolicyMultiple sclerosis disease-modifying agents (fingolimod, Mayzent)

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJul 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization with documentation showing neurologist involvement, diagnosis, prior therapy history, and required MRI/relapse evidence when applicable.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

LifetimeApproval length

NeurologistPrescriber requirement

≥1 relapseRequired relapse (Mayzent)

≥1Gadolinium lesion

Coverage Criteria for Fingolimod and Mayzent

Initial approval (fingolimod, Mayzent)

Covered when ALL of the following are met for fingolimod (generic) or Mayzent:

Core authorization requirements: Request is initiated by or under the supervision of a neurologist

Refer to prescriber requirement

Support for use: Use of the requested product is supported for the member's type of multiple sclerosis (MS), the requested duration of therapy, and the member's age

Document MS type, age, and requested duration

Monotherapy intent: Monotherapy with the requested product is intended

Prior therapy failure or contraindication: Member has failed (continued clinical relapses, CNS lesion progression on MRI, or worsening disability) while adherent to therapy, OR has contraindications to dimethyl fumarate

Applies to both fingolimod and Mayzent

Mayzent additional failure: For Mayzent only: member has failed (continuation of clinical relapses, CNS lesion progression on MRI, or worsening disability) while adherent to therapy, OR has contraindications to fingolimod

This node applies only when the requested product is Mayzent

Mayzent - Active secondary progressive MS criteria

Additional criteria specific to Mayzent for active secondary progressive MS:

Mayzent - active secondary progressive MS: 1) Diagnosis of active secondary progressive multiple sclerosis; 2) At least one relapse within the past 2 years; 3) Either failure/contraindication to dimethyl fumarate OR evidence of highly active disease OR failure/contraindication to fingolimod; 4) Monotherapy intent and neurologist involvement

Highly active disease defined in separate node

Mayzent - highly active disease: One of: a) >=1 relapse in the previous year while on therapy; OR b) >=1 gadolinium-enhancing lesion on MRI; OR c) significant T2 lesion burden defined as one of: >=10 T2 lesions on MRI, significant increase in T2 lesion load vs prior MRI, OR T2 lesion(s) in spinal cord or brainstem

Presence of highly active disease may satisfy the requirement in lieu of prior failure to dimethyl fumarate

The policy document does not list any explicit exclusions. There are no standalone exclusion statements or a separate excluded-indications section in the approval criteria.

While the guideline does not enumerate labeled “not medically necessary” conditions, the approval logic makes clear that requests lacking required elements would not meet medical necessity. Relevant deficiencies include absence of neurologist initiation or supervision, failure to document MS type/age/duration support for the requested product, lack of intent for monotherapy, or failure to show prior treatment failure or contraindication to dimethyl fumarate (and for Mayzent, to fingolimod when specified). These are the practical grounds on which a request would not be supported.

Key Clinical Thresholds and Imaging Findings

Relapse history

RequirementAt least one clinical relapse within the past 2 years

ContextApplies to members with a diagnosis of active secondary progressive multiple sclerosis requesting Mayzent

Documentation neededMedical record note confirming date and description of relapse within 2 years

Gadolinium-enhancing lesions

MRI finding>= 1 gadolinium-enhancing lesion on MRI

Role in criteriaCounts as evidence of highly active disease for Mayzent pathway

Documentation needed

Prior Authorization, Documentation, and Prescriber Requirements

Prior Authorization

Prior authorization required; lifetime approval when criteria met

Prior authorization is required for fingolimod (generic) and Mayzent; when all coverage criteria are met, approval length is listed as Lifetime (through 12/31/2039).

Step Therapy

Step therapy: documented prior treatment failure or contraindication required

Member must have failed therapy — defined as continuation of clinical relapses, CNS lesion progression on MRI, or worsening disability — while adherent to therapy, or have contraindications to dimethyl fumarate; for Mayzent, failure or contraindication to fingolimod is additionally required in some pathways.

Failure = continuation of clinical relapses, CNS lesion progression on MRI, or worsening disability while adherent
Mayzent-specific: failure/contraindication to fingolimod may also be required
Contraindication to dimethyl fumarate can substitute for prior failure

Definitions and Disease Activity

Highly active disease

DefinitionHighly active disease = one of: >=1 relapse in the previous year while on therapy; OR >=1 gadolinium-enhancing lesion on MRI; OR significant T2 lesion burden (>=10 T2 lesions, significant increase vs prior MRI, or T2 lesion(s) in spinal cord/brainstem)

UseMay satisfy requirement in lieu of failure to dimethyl fumarate for Mayzent pathway

EvidenceRequires clinical documentation and supporting MRI reports demonstrating the qualifying activity

Background

This guideline addresses use of fingolimod (generic) and siponimod (Mayzent) as disease-modifying therapies for relapsing forms of multiple sclerosis. For Mayzent the criteria include an additional requirement demonstrating prior failure or contraindication to fingolimod when applicable, and approved requests are listed with an approval length of Lifetime.